3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Lymphoma, Large B-Cell, Diffuse
4
Rhabdoid Tumor
3
Pinealoma
3
Neuroectodermal Tumors, Primitive
3
Neoplasms, Germ Cell and Embryonal
3
Medulloblastoma
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Follicular
3
Glioma
3
Ependymoma
3
Choroid Plexus Carcinoma
3
Central Nervous System Neoplasms
3
Brain Neoplasms
3
Recurrence
2
Lymphoma, Mantle-Cell
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Colorectal Neoplasms
2
Burkitt Lymphoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Lymphoma, B-Cell
1
Gliosarcoma
1
Glioblastoma
1
Diffuse Intrinsic Pontine Glioma
1
Dendritic Cell Sarcoma, Interdigitating
1
CD7-Positive Hematological Malignancies
1
Interventions
Temozolomide
85
Radiotherapy
51
Bevacizumab
31
Irinotecan
19
Radiation
16
Carmustine
15
Magnetic Resonance Spectroscopy
14
Erlotinib Hydrochloride
14
O(6)-benzylguanine
11
Chemotherapy, Adjuvant
11
Carboplatin
9
sargramostim
8
Thalidomide
8
Imatinib Mesylate
8
Filgrastim
8
Surgical Procedures, Operative
6
Gene Expression Profiling
6
Drug Therapy
6
pembrolizumab
5
aldesleukin
5
Topotecan
5
Radiotherapy, Intensity-Modulated
5
Hydroxyurea
5
Gefitinib
5
Etoposide
5
Sorafenib
4
Immunohistochemistry
4
Dasatinib
4
Celecoxib
4
Biopsy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gliosarcoma
×
Automobiles
×
Clear all
NCT02664363
2023-02-17
ExCeL
Duke University
Phase 1
Terminated
3 enrolled
8 charts